Sionna Therapeutics, Inc. · NASDAQ:SION
Sionna Therapeutics — Corporate Update (August 2026)
14 slides from Sionna Therapeutics's corporate update, Aug 10, 2026
Slide 1: Topline Data from Two NBD1 Stabilizer Programs
Sionna Therapeutics Topline Data from Two NBD1 Stabilizer Programs August 10, 2026
Slide 2: Disclaimers and forward-looking statements
Disclaimers and forward-looking statements This presentation contains forward-looking statements of Sionna Therapeutics, Inc. (“Sionna”, “the Company”, “we”, “us”, or “our”) that involve substantial risks and uncertainties. All statements other than historical factual information are forward-looking
Slide 3: Key takeaways from today’s announcement
Key takeaways from today’s announcement PreciSION CF Phase 2a did not meet key activity endpoint The trial demonstrated a -1.0 mmol/L mean placebo-adjusted sweat chloride change (p = 0.7) when SION-719 was added to Trikafta® We are not advancing development of SION-719 as an add-on to SOC We w
Slide 4: Agenda
Agenda SION-719 PreciSION CF Phase 2a Proof-of-Concept Trial 1 Topline Results SION-451 Phase 1 Healthy Volunteer Dual Combination Trial 2 Topline Results 3 Closing Remarks 4 Q&A 4
Slide 5: Phase 2a proof-of-concept trial evaluated SION-719 when added to Trikafta
PreciSION CF Phase 2a proof-of-concept trial evaluated SION-719 when added to Trikafta 28 Day 14 Day 14 Day 28 Day 14 Day 14 Day Endpoints Primary: Safety, Tolerability Secondary: Sweat Chloride, PK Phase 2a Sequence 1 n=6 SION-719 Placebo Trial powered for ≥10 mmol/L + Trikafta + Trikafta SwCl chan
Slide 6: Summary of baseline and demographic characteristics
Summary of baseline and demographic characteristics PreciSION CF enrolled adult CF participants homozygous for F508del who were stable on Trikafta for at least 3 months before screening Overall N=15 Age, years, mean (SD) 35.1 (7.9) Sex [n (%)] Female 7 (46.7) Male 8 (53.3) Ethnicity [n (%)] Non- His
Slide 7: PreciSION CF Phase 2a proof-of-concept trial results
PreciSION CF Phase 2a proof-of-concept trial results Mean placebo-adjusted sweat chloride change of -1.0 mmol/L (p = 0.7) when patients were taking a 30mg BID Key Activity dose of SION-719 on background of Trikafta Endpoint Potential trial confounders were observed, including SwCl variability, and d
Slide 8: SION-719 was generally well tolerated when added to Trikafta
SION-719 was generally well tolerated when added to Trikafta with most TEAEs mild to moderate Placebo SION-719 30mg BID Sequence 1 Sequence 2 Overall Sequence 1 Sequence 2 Overall Trial Participants (n) N=6 N=8 N=14 N=7* N=8 N=15* Total number of TEAEs 3 20 23 8 14 22 • Most TEAEs were mild to moder
Slide 9: Agenda
Agenda SION-719 PreciSION CF Phase 2a Proof-of-Concept Trial 1 Topline Results SION-451 Phase 1 Healthy Volunteer Dual Combination Trial 2 Topline Results 3 Closing Remarks 4 Q&A 9
Slide 10: Phase 1 clinical evaluation of SION-451 anchored dual combinations
Phase 1 clinical evaluation of SION-451 anchored dual combinations Trial Design & Conduct Trial Outcome • Evaluated the safety, tolerability, and PK profiles of • Trial achieved its safety, tolerability, and PK objectives, different dose combinations of SION-451 + SION-2222 including target exposure
Slide 11: SION-451 BID + SION-2222 QD demonstrated a favorable tolerability profile
SION-451 BID + SION-2222 QD demonstrated a favorable tolerability profile SION-451 BID + SION-451 BID + Placebo Total SION-2222 QD SION-2222 BID 3 cohorts 2 cohorts Trial Participants (n) (n=15) (n=27) (n=18) (n=60) Participants with any TEAE, n (%) 5 (33) 19 (70) 10 (56) 34 (57) SION-451 BID + SION
Slide 12: Agenda
Agenda SION-719 PreciSION CF Phase 2a Proof-of-Concept Trial 1 Topline Results SION-451 Phase 1 Healthy Volunteer Dual Combination Trial 2 Topline Results 3 Closing Remarks 4 Q&A 12
Slide 13: Next steps for Sionna following today’s clinical results
Next steps for Sionna following today’s clinical results Sionna does not plan to advance SION-719 as an add-on to SOC NEXT STEPS We will continue to analyze the results of the SION-719 PreciSION CF study, and assess implications for the SION-451 dual combination program ~$268 million in cash and cas
Slide 14: Agenda
Agenda SION-719 PreciSION CF Phase 2a Proof-of-Concept Trial 1 Topline Results SION-451 Phase 1 Healthy Volunteer Dual Combination Trial 2 Topline Results 3 Closing Remarks 4 Q&A 14